Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) EPS (Basic) (2016 - 2025)

Lisata Therapeutics filings provide 13 years of EPS (Basic) readings, the most recent being -$0.33 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 40.0% year-over-year to -$0.33, compared with a TTM value of -$1.91 through Dec 2025, up 20.42%, and an annual FY2025 reading of -$1.91, up 20.42% over the prior year.
  • EPS (Basic) hit -$0.33 in Q4 2025 for Lisata Therapeutics, up from -$0.49 in the prior quarter.
  • The five-year high for EPS (Basic) was -$0.33 in Q4 2025, with the low at -$0.77 in Q1 2023.
  • Median EPS (Basic) over the past 3 years was -$0.57 (2024), compared with a mean of -$0.57.
  • The sharpest move saw EPS (Basic) dropped 22.0% in 2024, then soared 40.0% in 2025.
  • Year by year, EPS (Basic) stood at -$0.66 in 2023, then increased by 16.67% to -$0.55 in 2024, then skyrocketed by 40.0% to -$0.33 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.33, -$0.49, and -$0.54 for Q4 2025, Q3 2025, and Q2 2025 respectively.